This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Array BioPharma's CEO Presents At Morgan Stanley Healthcare Conference - Transcript

Our other HemOnc program, 520 for multiple myeloma is very active as a single agent in heavily [protrude] patients about 20% response rate and over 8 months duration. And we are now studying in combination with dex carfilzomib and bortezomib. So, we look forward to that.

Partnering, we just (inaudible) about our data in our pain program 797at our primary end points and we are looking to partner that product and to maximize value, we asthma program that we reads out Phase 2 beginning actually May of next year at ATS and another potentially valuable partnerable product.

On our partnered portfolio we have 10 partnerships I'm not going to go through them all, but perhaps the most important to us is selumetinib partnered with AstraZeneca the MEK inhibitor that showed remarkable results in KRAS mutant lung cancer. At ASCO this year we expect AstraZeneca to continue the development of that product and look forward to them announcing their fore development plan in the near future. Novartis, actually the economics on the Novartis collaboration are substantially higher, so AstraZeneca made about double-digits upon success. Novartis has significantly higher royalties and that's what MEK162 which showed remarkable results NRAS mutant melanoma at ASCO and we expect them to move forward. We continue to very aggressively develop the product.

So, between the two internal program, the MEK inhibitors and danoprevir which Roche has indicated is a Phase 3 decision for the next year. We have five programs that maybe moving towards commercialization in the very near future.

Read the rest of this transcript for free on

3 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AAPL $93.99 0.00%
FB $102.01 0.00%
GOOG $682.40 0.00%
TSLA $151.04 0.00%
YHOO $27.04 0.00%


Chart of I:DJI
DOW 15,973.84 +313.66 2.00%
S&P 500 1,864.78 +35.70 1.95%
NASDAQ 4,337.5120 +70.6750 1.66%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs